Lawrence E. Flaherty

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak et al. · Journal of Clinical Oncology · 2000 · 922 citations

Pharmacy, Oncology, Pharmacotherapy +15

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

David F. McDermott, Meredith M. Regan, Joseph I. Clark et al. · Journal of Clinical Oncology · 2004 · 819 citations

Medicine, Oncology, Pharmacotherapy +15

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

Michael B. Atkins, Jessie J. Hsu, Gary I. Cohen et al. · Journal of Clinical Oncology · 2008 · 322 citations · Full text

Medicine, Oncology, Pharmacology +16

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Antoni Ribas, René González, Anna C. Pavlick et al. · The Lancet Oncology · 2014 · 295 citations

Medicine, Oncology, Pharmacology +12